These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

168 related articles for article (PubMed ID: 3910557)

  • 1. Graft-versus-host disease.
    Gale RP
    Immunol Rev; 1985 Dec; 88():193-214. PubMed ID: 3910557
    [No Abstract]   [Full Text] [Related]  

  • 2. Results of four different protocols for prophylaxis against graft-versus-host disease.
    Tollemar J; Ringdén O; Bäckman L; Janossy G; Lönnqvist B; Markling L; Philstedt P; Sundberg B
    Transplant Proc; 1989 Feb; 21(1 Pt 3):3008-10. PubMed ID: 2650414
    [No Abstract]   [Full Text] [Related]  

  • 3. Progress in bone marrow transplantation in man.
    Gale RP
    Surv Immunol Res; 1982; 1(1):40-66. PubMed ID: 6138827
    [No Abstract]   [Full Text] [Related]  

  • 4. Marrow transplantation for leukemia and aplastic anemia: two controlled trials of a combination of methotrexate and cyclosporine v cyclosporine alone or methotrexate alone for prophylaxis of acute graft-v-host disease.
    Storb R; Deeg HJ; Whitehead J; Farewell V; Appelbaum FR; Beatty P; Bensinger W; Buckner CD; Clift RA; Doney K
    Transplant Proc; 1987 Feb; 19(1 Pt 3):2608-13. PubMed ID: 3547942
    [No Abstract]   [Full Text] [Related]  

  • 5. T-cell depletion versus methotrexate as GvHD-prophylaxis in allogeneic bone marrow transplantation for leukaemia.
    Wiesneth M; Hertenstein B; Bunjes D; Schmeiser T; Arnold R; Heimpel H; Heit W
    Eur J Haematol; 1988 Sep; 41(3):243-9. PubMed ID: 3053241
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Cyclosporine v methotrexate for graft-v-host disease prevention in patients given marrow grafts for leukemia: long-term follow-up of three controlled trials.
    Storb R; Deeg HJ; Fisher L; Appelbaum F; Buckner CD; Bensinger W; Clift R; Doney K; Irle C; McGuffin R
    Blood; 1988 Feb; 71(2):293-8. PubMed ID: 3276360
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Prevention and treatment of acute graft-versus-host disease.
    Neudorf S; Filipovich A; Ramsay N; Kersey J
    Semin Hematol; 1984 Apr; 21(2):91-100. PubMed ID: 6377502
    [No Abstract]   [Full Text] [Related]  

  • 8. A randomized prospective trial comparing cyclosporine and methotrexate given for prophylaxis of graft-versus-host disease after bone marrow transplantation.
    Biggs JC; Atkinson K; Gillett E; Downs K; Concannon A; Dodds A
    Transplant Proc; 1986 Apr; 18(2):253-5. PubMed ID: 3515659
    [No Abstract]   [Full Text] [Related]  

  • 9. T cell depletion with CAMPATH-1 in allogeneic bone marrow transplantation.
    Hale G; Cobbold S; Waldmann H
    Transplantation; 1988 Apr; 45(4):753-9. PubMed ID: 3282358
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Efficacy of a short course (four doses) of methotrexate following bone marrow transplantation for prevention of graft-versus-host disease.
    Smith BR; Parkman R; Lipton J; Nathan DG; Rappeport JM
    Transplantation; 1985 Mar; 39(3):326-9. PubMed ID: 3883600
    [No Abstract]   [Full Text] [Related]  

  • 11. Bone marrow transplantation in acute nonlymphoblastic leukemia.
    Zwaan FE; Jansen J
    Semin Hematol; 1984 Jan; 21(1):36-42. PubMed ID: 6367055
    [No Abstract]   [Full Text] [Related]  

  • 12. Approaches to graft-versus-host disease following bone marrow transplantation in monkeys and man.
    Dicke KA; Spitzer G; Peters L; Stevens EE; Hendriks W; McCredie tkb
    Transplant Proc; 1978 Mar; 10(1):217-21. PubMed ID: 416529
    [No Abstract]   [Full Text] [Related]  

  • 13. Management of graft-versus-host disease.
    Ringdén O
    Eur J Haematol; 1993 Jul; 51(1):1-12. PubMed ID: 8348938
    [No Abstract]   [Full Text] [Related]  

  • 14. Decreased incidence and severity of graft-versus-host disease in HLA matched and mismatched marrow recipients of cyclosporine and methotrexate.
    Tollemar J; Ringdén O; Heimdahl A; Lönnqvist B; Sundberg B
    Transplant Proc; 1988 Jun; 20(3 Suppl 3):470-9. PubMed ID: 3291283
    [No Abstract]   [Full Text] [Related]  

  • 15. Methotrexate and cyclosporine compared with cyclosporine alone for prophylaxis of acute graft versus host disease after marrow transplantation for leukemia.
    Storb R; Deeg HJ; Whitehead J; Appelbaum F; Beatty P; Bensinger W; Buckner CD; Clift R; Doney K; Farewell V
    N Engl J Med; 1986 Mar; 314(12):729-35. PubMed ID: 3513012
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Prevention of graft versus host disease by in vitro depletion of T lymphocytes with monoclonal antibodies (Campath-1) in patients undergoing bone marrow transplantation].
    Iriondo A; Richard C; Hermosa V; Conde E; Garijo J; Cuadrado MA; Bello C; Muruzábal MJ; Pérez-Encinas M; Zubizarreta A
    Med Clin (Barc); 1988 Oct; 91(13):488-92. PubMed ID: 3067007
    [No Abstract]   [Full Text] [Related]  

  • 17. Graft-versus-host disease after marrow transplantation.
    Lancet; 1984 Mar; 1(8375):491-2. PubMed ID: 6142212
    [No Abstract]   [Full Text] [Related]  

  • 18. T cells, graft-versus-host disease and graft-versus-leukemia: innovative approaches for blood and marrow transplantation.
    Champlin R; Giralt S; Gajewski J
    Acta Haematol; 1996; 95(3-4):157-63. PubMed ID: 8677736
    [TBL] [Abstract][Full Text] [Related]  

  • 19. T-cell depletion to prevent graft-versus-host disease after bone marrow transplantation.
    Champlin R
    Hematol Oncol Clin North Am; 1990 Jun; 4(3):687-98. PubMed ID: 2193019
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Prevention of graft-versus-host disease with T cell depletion or cyclosporin and methotrexate. A randomized trial in adult leukemic marrow recipients.
    Ringdén O; Pihlstedt P; Markling L; Aschan J; Båryd I; Ljungman P; Lönnqvist B; Tollemar J; Janossy G; Sundberg B
    Bone Marrow Transplant; 1991 Mar; 7(3):221-6. PubMed ID: 2059758
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.